Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Símbolo de cotizaciónTLX
Nombre de la empresaTelix Pharmaceuticals Ltd
Fecha de salida a bolsaNov 15, 2017
Director ejecutivoOrtiz (Raphaeel)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección55 Flemington Road
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3051
Teléfono61390933855
Sitio Webhttps://telixpharma.com/
Símbolo de cotizaciónTLX
Fecha de salida a bolsaNov 15, 2017
Director ejecutivoOrtiz (Raphaeel)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos